Odronextamab Drug Asset Due Diligence Report 2026

This Odronextamab Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Odronextamab can convert its Bispecific T-cell Engager (BiTE) profile and CD20 x CD3 biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Odronextamab (query alias: odronextamab)
Modality / target	Bispecific T-cell Engager (BiTE); CD20 x CD3; CD20 inhibitors, CD3 stimulants, ADCC
Highest global status	Approved
Originator	Regeneron Pharmaceuticals, Inc.
Active developers	Regeneron Pharmaceuticals, Inc., Zai Lab (Shanghai) Co., Ltd., Regeneron Ireland DAC

The MCP disease footprint includes Diffuse large B-cell lymphoma recurrent, Diffuse large B-cell lymphoma refractory, Recurrent Follicular Lymphoma. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT07128641	Phase 2	Recruiting	35	Complete Response Rate (CRR)
NCT06854159	Phase 2	Recruiting	34	Complete response rate (CRR)
NCT06784726	Phase 2	Recruiting	27	Failure to undergo leukapheresis

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

First-line odronextamab (Odro) plus chemotherapy (CHOP) in diffuse large B-cell lymphoma (DLBCL): OLYMPIA-3 Part 1B results.

Phase 3; n=40; evaluation: Positive. Reported fields: TEAE = The most common TEAEs were neutropenia (57.5%), CRS (55.0%), and anemia (42.5%). CRS rates were consistent with Part 1A, predominantly Grade 1 (42.5% of pts). ICANS occurred in 3 pts (all Grade 1) and resolved completely. ; TEAE = The most common TEAEs were neutropenia (57.5%), CRS (55.0%), and anemia (42.5%). CRS rates were consistent with Part 1A, predominantly Grade 1 (42.5% of pts). ICANS occurred in 3 pts (all Grade 1) and resolved completely.

FIRST-LINE ODRONEXTAMAB PLUS CHOP IN DIFFUSE LARGE B-CELL LYMPHOMA: OLYMPIA-3 PART 1B RESULTS

Phase 3; n=40; evaluation: Positive. Reported fields: TEAE(CHOP dose reduction) = 5.0 % ; TEAE(CHOP dose reduction) = 10.0 %

ODRONEXTAMAB FOR RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA BEFORE AUTOLOGOUS CHIMERIC ANTIGEN RECEPTOR T CELL (CART) THERAPIES

Phase 2; n=27; evaluation: Positive. Reported fields: AE(grade 3/4) = 15.0 %

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Odronextamab addresses Diffuse large B-cell lymphoma recurrent, Diffuse large B-cell lymphoma refractory, Recurrent Follicular Lymphoma. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific T-cell Engager (BiTE)—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2020-04-08	Zai Lab collaborates with Regeneron to develop and market REGN-1979 for oncology in Mainland China, Hong Kong, Taiwan, and Macau.	Phase 2	US$30.0M upfront; US$160.0M milestones; US$190.0M stated total

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “NK cell engager proteins comprising Anti-CD20 and ant-nkp46 antibody, linked to il-2 in treatment of r/r b-nhl”. The milestone feed surfaced a patent-application signal described as “Use of Anti-CD3 antibody for selectively depleting activated t cells”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Cytokine-release syndrome, neurotoxicity, and infection
Durability after deep B-cell or plasma-cell depletion
Dose-step-up logistics, manufacturing, and outpatient feasibility

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO